[
  {
    "ts": null,
    "headline": "Bristol Myers Squibb : Preliminary Q2 2025 Acquired IPRD & Licensing Income",
    "summary": "BRISTOL-MYERS SQUIBB COMPANY Preliminary Estimated Second Quarter Impact of Acquired In-Process Research and Development and Licensing Income Three months ended...",
    "url": "https://finnhub.io/api/news?id=c3b836375a69a6b3791b62838a1849f5973b57a1e276c8748dc2053057c8bc6b",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751557508,
      "headline": "Bristol Myers Squibb : Preliminary Q2 2025 Acquired IPRD & Licensing Income",
      "id": 135739978,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "BRISTOL-MYERS SQUIBB COMPANY Preliminary Estimated Second Quarter Impact of Acquired In-Process Research and Development and Licensing Income Three months ended...",
      "url": "https://finnhub.io/api/news?id=c3b836375a69a6b3791b62838a1849f5973b57a1e276c8748dc2053057c8bc6b"
    }
  },
  {
    "ts": null,
    "headline": "Will The Decline in Legacy Drugs Pull Down BMY's Top Line?",
    "summary": "Bristol Myers' legacy drug sales plunged 20% amid generic erosion and Medicare changes, spotlighting its shift to a newer growth portfolio.",
    "url": "https://finnhub.io/api/news?id=a4e387343a3a6918ad3fbf09e0437150305b11952c4db58010ec5bc441a4ebe3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751549160,
      "headline": "Will The Decline in Legacy Drugs Pull Down BMY's Top Line?",
      "id": 135735715,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers' legacy drug sales plunged 20% amid generic erosion and Medicare changes, spotlighting its shift to a newer growth portfolio.",
      "url": "https://finnhub.io/api/news?id=a4e387343a3a6918ad3fbf09e0437150305b11952c4db58010ec5bc441a4ebe3"
    }
  }
]